Study guide
6.13 Nutrition, Natural Health Products, and Complementary Medicine
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
6.13 Nutrition, Natural Health Products, and Complementary Medicine
Key Takeaways Explain This Topic AI
Natural health products sold in Canada carry an eight-digit Natural Product Number or Homeopathic Medicine Number issued by Health Canada under the Natural Health Products Regulations.
St. John's wort induces CYP3A4 and P-glycoprotein and can cause failure of contraceptives, transplant immunosuppressants, direct oral anticoagulants, and antiretrovirals.
Vitamin K in green vegetables and in some supplements antagonises warfarin; the counselling message is dietary consistency rather than avoidance.
Adults over 50 should obtain 400 to 1,000 IU of vitamin D daily, and adults over 50 need a vitamin B12 supplement or fortified foods because food-bound B12 absorption declines with age.
Refeeding syndrome causes a rapid fall in phosphate, potassium, and magnesium when nutrition is restarted in a severely malnourished patient and requires slow initiation with thiamine.
Last updated: August 2026
6.13 Nutrition, Natural Health Products, and Complementary Medicine
Exam Focus: The PEBC syllabus lists complementary and alternative medicine, natural health products, and the application of nutrition and supplements explicitly under Pharmacotherapeutics. Items test regulatory recognition, interaction screening, and the ability to give an evidence-based answer without dismissing the patient.
Nutrition Assessment in Pharmacy Practice
Nutrition status is assessed from unintended weight change, dietary intake, physical signs, and biochemistry. A loss of more than 5% of body weight in one month, or 10% in six months, is clinically significant.
Canada's Food Guide replaced the older serving-based model with a plate proportion — roughly half vegetables and fruit, one quarter whole grain foods, one quarter protein foods — alongside water as the drink of choice and guidance to limit highly processed foods.
Populations needing targeted supplementation:
- Population Recommendation
- People who could become pregnant Folic acid 0.4 to 1 mg daily, higher with risk factors
- Exclusively breastfed infants Vitamin D 400 IU daily
- Adults over 50 Vitamin D 400 to 1,000 IU daily; vitamin B12 from supplements or fortified foods
- Vegans Vitamin B12, and attention to iron, zinc, calcium, iodine, and omega-3 fatty acids
- Post-bariatric surgery Lifelong multivitamin plus iron, calcium citrate, vitamin D, and vitamin B12
Refeeding syndrome occurs when nutrition is reintroduced to a severely malnourished patient: the insulin surge drives phosphate, potassium, and magnesium into cells, producing cardiac and neurological complications. Prevention requires slow reintroduction of energy, thiamine before or with the first feed, and close electrolyte monitoring.
Vitamins and Minerals: Practical Points
Vitamin D is measured as 25-hydroxyvitamin D. Deficiency is common in Canada because of latitude. Toxicity from prolonged very high doses causes hypercalcemia, nausea, and kidney injury.
Calcium absorption is best in doses of 500 mg or less at a time. Calcium carbonate needs gastric acid and is taken with food; calcium citrate does not and is preferred with proton pump inhibitor therapy or after bariatric surgery.
Iron is discussed in the hematology section; the key interaction set is calcium, antacids, proton pump inhibitors, tetracyclines, quinolones, and levothyroxine.
Potassium and magnesium supplements interact with renin-angiotensin blockers and potassium-sparing diuretics.
Fat-soluble vitamins (A, D, E, K) accumulate. High-dose vitamin A is teratogenic; vitamin E at high doses increases bleeding risk with anticoagulants.
The Canadian Regulatory Framework
Natural health products are regulated under the Natural Health Products Regulations made under the Food and Drugs Act . A product legally sold in Canada carries a Natural Product Number (NPN) or, for homeopathic preparations, a Homeopathic Medicine Number (DIN-HM) — an eight-digit identifier confirming that Health Canada has reviewed the product for safety, efficacy, and quality, and has authorised its label claims.
This is a genuine but limited assurance. It does not mean the product has been tested against a prescription therapy, and product-to-product variability in botanical content remains a real problem. Adverse reactions to natural health products are reported to Health Canada through the Canada Vigilance Program , exactly as for drugs.
Pharmacists must ask about natural health product use directly, because patients frequently do not volunteer it and do not classify these products as medicines. Record them on the medication profile.
Commonly Used Products, Evidence, and Interactions
Product Common use Evidence Interaction and safety concerns
St. John's wort Mild to moderate depression Some benefit in mild depression Potent CYP3A4 and P-glycoprotein inducer : contraceptive failure, transplant rejection, reduced direct oral anticoagulant, antiretroviral, and cyclosporine levels; serotonin syndrome with serotonergic drugs
Ginkgo biloba Cognition, claudication Weak and inconsistent Bleeding risk with anticoagulants and antiplatelets; seizure risk
- Garlic, ginger, ginseng, feverfew Various Limited Additive antiplatelet or anticoagulant effect
- Echinacea Cold prevention Inconsistent Caution in autoimmune disease
Glucosamine and chondroitin Osteoarthritis Not consistently better than placebo Shellfish-derived products; glucose monitoring in diabetes
Saw palmetto Benign prostatic hyperplasia Not better than placebo in good trials May confound prostate-specific antigen interpretation
Melatonin Insomnia, jet lag Modest, best for circadian phase shift Sedation; interacts with fluvoxamine
Fish oil (omega-3) Triglyceride lowering Effective at high doses for hypertriglyceridemia Bleeding risk at high doses; atrial fibrillation signal
Valerian, kava Anxiety, insomnia Weak Kava is associated with severe hepatotoxicity
Probiotics Antibiotic-associated diarrhea Modest benefit for some strains Avoid in severe immunosuppression and central venous catheters
Warfarin and vitamin K deserve a separate note. Leafy green vegetables, and some multivitamins and nutritional supplement drinks, contain vitamin K that antagonises warfarin. The correct counselling is consistency , not avoidance: keep intake stable week to week so the international normalized ratio stays stable, and tell the anticoagulation clinic when diet changes substantially.
Answering the Complementary Medicine Question Well
A dismissive answer ends the conversation and drives the use underground, where interactions go undetected. A professional response has four parts:
Ask openly what the patient is taking and what outcome they hope for.
Screen for interactions and contraindications against the full medication profile, including the specific inducer, bleeding, and serotonergic risks above.
Give the evidence honestly , distinguishing "no good evidence of benefit" from "evidence of harm".
Agree on monitoring and a decision point — how the patient will judge whether it is working, and when to stop.
Never recommend that a patient replace an effective prescription therapy with a natural health product, and never endorse a product for a serious condition on testimonial evidence alone.